1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

MM - 386

Baseline Risk Modifiers for Multiple Myeloma Following Herpes Zoster: A Multicenter Retrospective Cohort Study

Aditya Anand

Poster Presenter: Aditya Anand

$Thumbnail for Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial$

MM - 1168

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Robert Rifkin

Poster Presenter: Robert Rifkin

Video

SOHO 2026 Annual Meeting

Posters by Title

Baseline Risk Modifiers for Multiple Myeloma Following Herpes Zoster: A Multicenter Retrospective Cohort Study

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Belantamab Mafodotin Combinations in Relapsed or Refractory Multiple Myeloma: Re-emergence of BCMA Antibody-Drug Conjugate Therapy Across Clinical Trials

Belantamab Mafodotin Triplets Versus Active-Control Triplets in Relapsed or Refractory Multiple Myeloma

Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study

Benefits of Rituximab Maintenance After First-Line Bendamustine-Rituximab in Mantle Cell Lymphoma: A Meta-Analysis of Clinical Trials and Observational Studies

Beta-Blocker Use During Plasma Cell-Directed Chemotherapy in AL Cardiac Amyloidosis: A Propensity-Matched Real-World TriNetX Analysis

Beyond a benign label: Mortality Trends Associated with Monoclonal Gammopathy of Undetermined Significance Among Adults Aged =45 Years in the United States, 1999-2024

Beyond a Single Entity: Site-Specific Heterogeneity in Clinical Characteristics, Treatment Patterns, and Survival Outcomes Among Patients With Plasmacytoma